Agios Pharmaceuticals to provide AG-221 Phase 1 study results at EHA meeting Agios Pharmaceuticals.

Agios Pharmaceuticals to provide AG-221 Phase 1 study results at EHA meeting Agios Pharmaceuticals, Inc. , a leader in the fields of cancer metabolism and inborn mistakes of metabolism , today announced that new scientific data from the Stage 1 study of AG-221, an available orally, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted within an oral display at the 19th Congress of the European Hematology Association taking place June 12 -15, 2014 in Milan, Italy http://www.sildenafilini.com/age-related-macular-degeneration.html .